Drug intelligence / Profile preview

Pearlium + EffectiCal

Development stage: Unknown
Lead developer: University of Alberta
Modality: Small Molecules
Administration: Oral

Overview

Pearlium + EffectiCal is a novel calcium, vitamin D, and mineral formulation developed by the University of Alberta to optimize calcium solubility and absorption. The product's base formulation, known as Formulation A5, has shown a three-fold increase in calcium retention compared to conventional calcium carbonate in preclinical studies. This enhanced bioavailability allows for a lower therapeutic dose, which is intended to minimize common gastrointestinal side effects such as constipation. It is currently being evaluated in Phase 4 clinical trials for the prevention of bone loss in postmenopausal women, where its efficacy is measured by the suppression of bone turnover markers.

Other names: Pearlium/Effecti-Cal

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Pearlium + EffectiCal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pearlium + EffectiCal.

Explore the full profile